Mutational hotspot regions for drug resistance via Tp53+/+- and Tp53+/−-mediated pathways are located on chromosome 1 and chromosome 11, respectively, and are related to prognosis of lung cancer cohorts. The gene discussed is TP53; the disease is lung cancer.